Top

Published in:

01-06-2009 | Review

Advanced glycation end products and C-peptide—modulators in diabetic vasculopathy and atherogenesis

Authors: Daniel Walcher, Nikolaus Marx

Published in: Seminars in Immunopathology | Issue 1/2009

Abstract

Patients with insulin resistance and early type 2 diabetes exhibit an increased propensity to develop a diffuse and extensive pattern of arteriosclerosis. Diabetic subjects show a remarkable increase in vascular complications, including myocardial infarction and strokes. The accelerated atherosclerosis in these patients is likely to be multifactorial. In this review, we focus on the advanced glycation end product (AGE)–receptor for AGE (RAGE) axis and the role of C-peptide as a mediator of lesion development. AGEs are proteins or lipids that become glycated after exposure to sugars. By engaging the RAGEs, AGEs induce the expression of proinflammatory mediators in various vascular cell types and are involved in a variety of microvascular and macrovascular complications. In animal models, interruption of the AGE–RAGE interaction reduces lesion size and plaque development and RAGE deficiency in a RAGE^−/−/apolipoprotein E^−/− double knockout mouse attenuates the development of atherosclerosis in diabetes. On the other side, patients with type 2 diabetes show increased levels of C-peptide and over the last years various groups examined the effect of C-peptide in vascular cells as well as its potential role in lesion development. Recent data suggest that the proinsulin cleavage product C-peptide could play a causal role in atherogenesis by promoting monocyte and CD4-positive lymphocyte recruitment in early arteriosclerotic lesions and by inducing the proliferation of vascular smooth muscle cells. The following review will summarize these two pathophysiological aspects and discuss on the one hand the potential role of the activated AGE–RAGE axis in diabetes-accelerated atherogenesis and on the other hand the role of C-peptide as a mediator in lesion development in patients with type 2 diabetes.

Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287(19):2570–2581CrossRefPubMed

Schmidt AM, Yan SD, Wautier JL et al (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84(5):489–497PubMed

Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2(5):430–436. doi:10.1007/s11883-000-0082-4 CrossRefPubMed

Degryse B, Bonaldi T, Scaffidi P et al (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152(6):1197–1206CrossRefPubMed

Neeper M, Schmidt AM, Brett J et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21):14998–15004PubMed

Ritthaler U, Deng Y, Zhang Y et al (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146(3):688–694PubMed

Lin RY, Choudhury RP, Cai W et al (2003) Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168(2):213–220. doi:10.1016/S0021-9150(03)00050-9 CrossRefPubMed

Soro-Paavonen A, Watson AM, Li J, Paavonen K et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57(9):2461–2469. doi:10.2337/db07-1808 CrossRefPubMed

Wahren J, Ekberg K, Jörnvall H (2007) C-peptide is a bioactive peptide. Diabetologia 50(3):503–509. doi:10.1007/s00125-006-0559-y CrossRefPubMed

10.

Wahren J, Shafqat J, Johansson J et al (2004) Molecular and cellular effects of C-peptide—new perspectives on an old peptide. Exp Diabesity Res 5(1):15–23. doi:10.1080/15438600490424479 CrossRefPubMed

11.

Kitamura T, Kimura K, Jung BD et al (2001) Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3 T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J 355(Pt 1):123–129. doi:10.1042/0264-6021:3550123 CrossRefPubMed

12.

Kitamura T, Kimura K, Jung BD et al (2002) Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 366(Pt 3):737–744PubMed

13.

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340(2):115–126CrossRefPubMed

14.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695CrossRefPubMed

15.

Libby P, Geng YJ, Aikawa M et al (1996) Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 7(5):330–335. doi:10.1097/00041433-199610000-00012 CrossRefPubMed

16.

Robertson AK, Hansson GK (2006) T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 26(11):2421–2432. doi:10.1161/01.ATV.0000245830.29764.84 CrossRefPubMed

17.

Marx N (2003) Diabetes und Arteriosklerose. Diabetes Stoffwechsel 4:205–211

18.

Libby P, Simon DI (2001) Inflammation and thrombosis: the clot thickens. Circulation 103(13):1718–1720PubMed

19.

Schmidt AM, Hasu M, Popov D et al (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91(19):8807–8811CrossRefPubMed

20.

Bierhaus A, Illmer T, Kasper M et al (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96(7):2262–2271PubMed

21.

Chavakis T, Bierhaus A, Al-Fakhri N et al (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198(10):1507–1515CrossRefPubMed

22.

Rouhiainen A, Kuja-Panula J, Wilkman E et al (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104(4):1174–1182CrossRefPubMed

23.

Tsuji H, Iehara N, Masegi T (1998) Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 245(2):583–588CrossRefPubMed

24.

Esposito C, Gerlach H, Brett J et al (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170(4):1387–1407CrossRefPubMed

25.

Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87(2):432–438. doi:10.1172/JCI115014 CrossRefPubMed

26.

Tan KC, Chow WS, Ai VH et al (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25(6):1055–1059. doi:10.2337/diacare.25.6.1055 CrossRefPubMed

27.

Rojas A, Romay S, González D et al (2000) Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 86(3):E50–E54PubMed

28.

Chakravarthy U, Hayes RG, Stitt AW et al (1998) Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47(6):945–952. doi:10.2337/diabetes.47.6.945 CrossRefPubMed

29.

Vlassara H, Brownlee M, Manogue KR et al (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240(4858):1546–1548CrossRefPubMed

30.

Kirstein M, Brett J, Radoff S, Ogawa S et al (1990) Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A 87(22):9010–9014. doi:10.1073/pnas.87.22.9010 CrossRefPubMed

31.

Kirstein M, Aston C, Hintz R et al (1992) Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 90(2):439–446. doi:10.1172/JCI115879 CrossRefPubMed

32.

Miyata T, Inagi R, Iida Y et al (1994) Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 93(2):521–528. doi:10.1172/JCI117002 CrossRefPubMed

33.

Cipollone F, Fazia ML (2006) COX-2 and atherosclerosis. J Cardiovasc Pharmacol 47(Suppl 1):S26–S36. doi:10.1097/00005344-200605001-00006 CrossRefPubMed

34.

Iwashima Y, Eto M, Hata A et al (2000) Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277(2):368–380CrossRefPubMed

35.

Isoda K, Folco EJ, Shimizu (2007) AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 192(2):298–304. doi:10.1016/j.atherosclerosis.2006.07.023 CrossRefPubMed

36.

Ichikawa K, Yoshinari M, Iwase M et al (1998) Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 136(2):281–287. doi:10.1016/S0021-9150(97)00221-9 CrossRefPubMed

37.

Higashi T, Sano H, Saishoji T et al (1997) The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 46(3):463–472. doi:10.2337/diabetes.46.3.463 CrossRefPubMed

38.

Wang R, Kudo M, Yokoyama M et al (2001) Roles of advanced glycation end products (AGE) and receptor for AGE on vascular smooth muscle cell growth. J Nippon Med Sch 68(6):472–481. doi:10.1272/jnms.68.472 CrossRefPubMed

39.

Wolf YG, Rasmussen LM, Ruoslahti E (1994) Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93(3):1172–1178. doi:10.1172/JCI117070 CrossRefPubMed

40.

Li JH, Huang XR, Zhu HJ et al (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18(1):176–178. doi:10.1096/fj.04-2273com CrossRefPubMed

41.

Porto A, Palumbo R, Pieroni M et al (2006) Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 20(14):2565–2566. doi:10.1096/fj.06-5867fje CrossRefPubMed

42.

Reddy MA, Li SL, Sahar S et al (2006) Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem 281(19):13685–13693CrossRefPubMed

43.

Park L, Raman KG, Lee KJ et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4(9):1025–1031. doi:10.1038/2012 CrossRefPubMed

44.

Bucciarelli LG, Wendt T, Qu W et al (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106(22):2827–2835CrossRefPubMed

45.

Wendt T, Harja E, Bucciarelli L et al (2006) RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185(1):70–77. doi:10.1016/j.atherosclerosis.2005.06.013 CrossRefPubMed

46.

Rozenman Y, Sapoznikov D, Mosseri M et al (1997) Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation. J Am Coll Cardiol 30(6):1420–1425. doi:10.1016/S0735-1097(97)00342-2 CrossRefPubMed

47.

Abizaid A, Kornowski R, Mintz GS et al (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32(3):584–589. doi:10.1016/S0735-1097(98)00286-1 CrossRefPubMed

48.

Sakaguchi T, Yan SF, Yan SD et al (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111(7):959–972PubMed

49.

Zhou Z, Wang K, Penn MS et al (2003) Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107(17):2238–2243. doi:10.1161/01.CIR.0000063577.32819.23 CrossRefPubMed

50.

Liliensiek B, Weigand MA, Bierhaus A et al (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113(11):1641–1650PubMed

51.

Malherbe P, Richards JG, Gaillard H et al (1999) cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 71(2):159–170. doi:10.1016/S0169-328X(99)00174-6 CrossRefPubMed

52.

Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370(Pt 3):1097–1109. doi:10.1042/BJ20021371 CrossRefPubMed

53.

Schlueter C, Hauke S, Flohr AM et al (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim Biophys Acta 1630(1):1–6PubMed

54.

Park IH, Yeon SI, Youn JH et al (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40(16):1203–1211. doi:10.1016/j.molimm.2003.11.027 CrossRefPubMed

55.

Schmidt AM, Vianna M, Gerlach M et al (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267(21):14987–14997PubMed

56.

Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83(11):876–886. doi:10.1007/s00109-005-0688-7 CrossRefPubMed

57.

Shoji T, Koyama H, Morioka T et al (2006) Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55(8):2245–2255. doi:10.2337/db05-1375 CrossRefPubMed

58.

Koyama H, Shoji T, Fukumoto S et al (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27(1):147–153. doi:10.1161/01.ATV.0000251502.88818.4b CrossRefPubMed

59.

Tan KC, Shiu SW, Chow W et al (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49(11):2756–2762. doi:10.1007/s00125-006-0394-1 CrossRefPubMed

60.

Humpert PM, Djuric Z, Kopf S et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9CrossRefPubMed

61.

Marx N, Walcher D, Raichle C et al (2004) C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24(3):540–545. doi:10.1161/01.ATV.0000116027.81513.68 CrossRefPubMed

62.

Walcher D, Aleksic M, Jerg V et al (2004) C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 53(7):1664–1670. doi:10.2337/diabetes.53.7.1664 CrossRefPubMed

63.

Al-Rasheed NM, Chana RS, Baines RJ et al (2004) Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 279(48):49747–49754. doi:10.1074/jbc.M408268200 CrossRefPubMed

64.

Bittl JA (1996) Advances in coronary angioplasty. N Engl J Med 335(17):1290–1302CrossRefPubMed

65.

Stone GW, Ellis SG, Cox DA et al (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109(16):1942–1947. doi:10.1161/01.CIR.0000127110.49192.72 CrossRefPubMed

66.

Kobayashi Y, Naruse K, Hamada Y et al (2005) Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 48:2396–2401. doi:10.1007/s00125-005-1942-9 CrossRefPubMed

67.

Walcher D, Babiak C, Poletek P et al (2006) C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 99(11):1181–1187. doi:10.1161/01.RES.0000251231.16993.88 CrossRefPubMed

68.

Cho HM, Choi SH, Hwang KC et al (2005) The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL. Mol Cells 19(1):60–66PubMed

69.

Beijersbergen RL, Bernards R (1996) Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 1287(2–3):103–120PubMed

70.

Harbour JW, Dean DC (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2(4):E65–E67. doi:10.1038/35008695 CrossRefPubMed

Title: Advanced glycation end products and C-peptide—modulators in diabetic vasculopathy and atherogenesis
Authors: Daniel Walcher
Nikolaus Marx
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2009
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-009-0144-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Vaccination against atherosclerosis? Induction of atheroprotective immunity

CRP and the risk of atherosclerotic events

Cytokine network and T cell immunity in atherosclerosis

Update on statin-mediated anti-inflammatory activities in atherosclerosis

The emerging role of the endocannabinoid system in cardiovascular disease

Obstructive sleep apnea, immuno-inflammation, and atherosclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials